Serum neurofilament is associated with progression of brain atrophy and disability in early MS

Objective: To investigate a potential effect of riluzole on serum neurofilaments (Nf) compared to placebo and the relationship between longitudinal clinical and MRI outcomes and serum Nf levels. Methods: Serum samples were obtained from participants enrolled in a randomized double-blind trial of neuroprotection with riluzole vs placebo as an add-on to weekly interferon-β (IFN-β)–1a IM initiated 3 months after randomization. Nf measurements were performed by ELISA and electrochemiluminescence immunoassay. Results: Longitudinal serum samples were available from 22 riluzole and 20 placebo participants over 24 months. There was no observed treatment effect with riluzole. Nf light chain (NfL) levels decreased over time (p = 0.007 at 24 months), whereas the Nf heavy chain was unchanged (p = 0.997). Changes in NfL were correlated with EDSS change (p = 0.009) and neuropsychological outcomes. Brain volume decreased more rapidly in patients with high baseline NfL (p = 0.05 at 12 months and p = 0.008 at 24 months) and this relationship became stronger at 24 months (p = 0.024 for interaction). Higher and increasing NfL predicted higher number of gadolinium-enhancing lesions (p < 0.001 for both). Conclusions: Our findings support the potential value of serum NfL as a marker of neuroaxonal injury in early multiple sclerosis. Its reduction over time could represent regression to the mean, or a possible treatment effect of IFN-β-1a. The association with whole brain atrophy and the formation of acute white matter lesions has relevant implications to use serum NfL as a noninvasive biomarker of the overall consequences of brain damage and ongoing disease activity. ClinicalTrials.gov identifier: NCT00501943.

[1]  J. Salzer,et al.  Neurofilament light as a prognostic marker in multiple sclerosis , 2010, Multiple sclerosis.

[2]  J. Julien,et al.  Normal dendritic arborization in spinal motoneurons requires neurofilament subunit L , 2002, The Journal of comparative neurology.

[3]  A. Petzold The prognostic value of CSF neurofilaments in multiple sclerosis at 15-year follow-up , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[4]  Henrik Zetterberg,et al.  Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa , 2016, Clinical chemistry and laboratory medicine.

[5]  T. Tombaugh,et al.  A comprehensive review of the Paced Auditory Serial Addition Test (PASAT). , 2006, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

[6]  K. Angelides,et al.  Characterization of mammalian neurofilament triplet proteins. Subunit stoichiometry and morphology of native and reconstituted filaments. , 1985, The Journal of biological chemistry.

[7]  C. McCulloch,et al.  A randomized controlled phase II trial of riluzole in early multiple sclerosis , 2014, Annals of clinical and translational neurology.

[8]  Bin Zhang,et al.  Requirement of Heavy Neurofilament Subunit in the Development of Axons with Large Calibers , 1998, The Journal of cell biology.

[9]  Gerry Shaw,et al.  Hyperphosphorylated neurofilament NF-H is a serum biomarker of axonal injury. , 2005, Biochemical and biophysical research communications.

[10]  A. Minagar Axonal Damage in Relapsing Multiple Sclerosis is Markedly Reduced by Natalizumab , 2011 .

[11]  Cristina Granziera,et al.  Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity , 2016, Multiple sclerosis.

[12]  David H. Miller,et al.  Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS – Neurofilament as a Surrogate of Disease Progression , 2013, PloS one.

[13]  L. Kappos,et al.  Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis , 2015, Neurology.